P
Paul G. Richardson
Researcher at Harvard University
Publications - 1631
Citations - 174221
Paul G. Richardson is an academic researcher from Harvard University. The author has contributed to research in topics: Multiple myeloma & Bortezomib. The author has an hindex of 183, co-authored 1533 publications receiving 155912 citations. Previous affiliations of Paul G. Richardson include Broomfield Hospital & Dartmouth College.
Papers
More filters
Journal ArticleDOI
Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma
Niels W.C.J. van de Donk,Philippe Moreau,Torben Plesner,Antonio Palumbo,Jacob P. Laubach,Fabio Malavasi,Hervé Avet-Loiseau,Maria-Victoria Mateos,Pieter Sonneveld,Henk M. Lokhorst,Paul G. Richardson +10 more
TL;DR: Although elotuzumab (anti-SLAMF7) has no single agent activity in advanced MM, randomized trials in relapsed/refractory MM have demonstrated significantly improved progression-free survival when elotzumab is added to lenalidomide-dexamethasone or bortezomib-dExamethAsone.
Journal ArticleDOI
A Novel Carbohydrate-Based Therapeutic GCS-100 Overcomes Bortezomib Resistance and Enhances Dexamethasone-Induced Apoptosis in Multiple Myeloma Cells
Dharminder Chauhan,Guilan Li,Klaus Podar,Teru Hideshima,Paola Neri,Deli He,Nicholas Mitsiades,Paul G. Richardson,Yan Chang,Joanne Schindler,Bradley Carver,Kenneth C. Anderson +11 more
TL;DR: The findings provide the framework for clinical evaluation of GCS-100, either alone or in combination with dexamethasone, to inhibit tumor growth, overcome drug resistance, and improve outcome for patients with this universally fatal hematologic malignancy.
Journal ArticleDOI
Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study
Suzanne Trudel,Nikoletta Lendvai,Nikoletta Lendvai,Rakesh Popat,Peter M. Voorhees,Brandi Reeves,Edward N. Libby,Paul G. Richardson,Axel Hoos,Ira Gupta,Veronique Bragulat,Zangdong He,Joanna Opalinska,Adam D. Cohen +13 more
TL;DR: GSK2857916 was well tolerated and demonstrated a rapid, deep and durable response in heavily pre-treated patients with relapsed/refractory multiple myeloma, consolidating the interim analyses conclusions that GSK 2857916 is a promising treatment for these patients.
Journal ArticleDOI
Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosis
Kenji Ishitsuka,Teru Hideshima,Teru Hideshima,Teru Hideshima,Makoto Hamasaki,Makoto Hamasaki,Makoto Hamasaki,Noopur Raje,Noopur Raje,Noopur Raje,Shaji Kumar,Shaji Kumar,Shaji Kumar,Hiromasa Hideshima,Hiromasa Hideshima,Hiromasa Hideshima,Norihiko Shiraishi,Norihiko Shiraishi,Norihiko Shiraishi,Hiroshi Yasui,Hiroshi Yasui,Hiroshi Yasui,Aldo M. Roccaro,Aldo M. Roccaro,Aldo M. Roccaro,Paul G. Richardson,Paul G. Richardson,Paul G. Richardson,Klaus Podar,Klaus Podar,Klaus Podar,Steven Le Gouill,Steven Le Gouill,Steven Le Gouill,Dharminder Chauhan,Dharminder Chauhan,Dharminder Chauhan,Kazuo Tamura,Kazuo Tamura,Kazuo Tamura,Jack L. Arbiser,Jack L. Arbiser,Jack L. Arbiser,Kenneth C. Anderson,Kenneth C. Anderson,Kenneth C. Anderson +45 more
TL;DR: HNK enhances MM cell cytotoxicity and apoptosis induced by bortezomib, and represses tube formation by endothelial cells, suggesting that HNK inhibits neovascurization in the bone marrow microenvironment.
Journal ArticleDOI
Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma
Paul G. Richardson,Sundar Jagannath,Mohamad A. Hussein,James R. Berenson,Seema Singhal,David Irwin,Stephanie F. Williams,William I. Bensinger,Ashraf Badros,Robert Vescio,Laurie Kenvin,Zhinuan Yu,Marta Olesnyckyj,Jerome B. Zeldis,Robert Knight,Kenneth C. Anderson +15 more
TL;DR: Treatment with single-agent lenalidomide monotherapy is active in relapsed and refractory multiple myeloma with acceptable toxicities, and its use in steroid-sparing combination approaches is supported.